Our experiments demonstrated that 5-aza-dC significantly induced the COL1A1 expression in CFs at both mRNA and protein levels, which is consistent with the results of TGF-β1 treatment. The gene discussed is TGFB1; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.